TERAPI4.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: Technology NT60 (Q2867071)

From EU Knowledge Graph
Revision as of 09:50, 13 December 2021 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in de, and other parts: Adding German translations)
Jump to navigation Jump to search
Project Q2867071 in Portugal
Language Label Description Also known as
English
TERAPI4.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: Technology NT60
Project Q2867071 in Portugal

    Statements

    0 references
    25,000.0 Euro
    0 references
    50,000.0 Euro
    0 references
    50.0 percent
    0 references
    1 April 2020
    0 references
    1 April 2023
    0 references
    BSIM THERAPEUTICS, S.A.
    0 references
    Q2988326 (Deleted Item)
    0 references

    40°12'40.28"N, 8°25'46.06"W
    0 references
    O projeto TERAPI4 visa a proteção dos direitos de Propriedade Intelectual de uma nova classe de agentes terapêuticos contra doenças amiloides raras de transtirretina. Estes novos compostos são pequenas moléculas pertencentes à série química NT60 desenvolvida pela BSIM Therapeutics. (Portuguese)
    0 references
    The TERAPI4 project aims to protect the intellectual property rights of a new class of therapeutic agents against rare amyloid transthyretin diseases. These new compounds are small molecules belonging to the NT60 chemical series developed by BSIM Therapeutics. (English)
    7 July 2021
    0 references
    Le projet TERAPI4 vise à protéger les droits de propriété intellectuelle d’une nouvelle classe d’agents thérapeutiques contre les rares maladies amyloïdes transthyrétines. Ces nouveaux composés sont de petites molécules appartenant à la série chimique NT60 développée par BSIM Therapeutics. (French)
    4 December 2021
    0 references
    Das Projekt TERAPI4 zielt darauf ab, die Rechte des geistigen Eigentums einer neuen Klasse von therapeutischen Wirkstoffen gegen seltene Transthyretin-Amyloiderkrankungen zu schützen. Diese neuen Verbindungen sind kleine Moleküle der von BSIM Therapeutics entwickelten NT60-Chemikalienserie. (German)
    13 December 2021
    0 references
    Coimbra
    0 references

    Identifiers

    CENTRO-01-0247-FEDER-046897
    0 references